Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: Impact of adjuvant chemotherapy

British Journal of Cancer

Volumn 111, Issue 5, 2014, Pages 1004-1013

  Kriege, M ^a   Hollestelle, A ^a   Jager, A ^a   Huijts, P E A ^b   Berns, E M ^a   Sieuwerts, A M ^a   Meijer Van Gelder, M E ^a   Collee J M ^c   Devilee, P ^b   Hooning, M J ^a   Martens, J W M ^a   Seynaeve, C ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

adjuvant chemotherapy; breast cancer; CHEK2 1100delC; contralateral breast cancer; survival

Indexed keywords

ANTHRACYCLINE; AROMATASE INHIBITOR; CHECKPOINT KINASE 2; GONADORELIN; TAMOXIFEN; TAXANE DERIVATIVE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; CONTRALATERAL BREAST CANCER; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FAMILIAL CANCER; FAMILY HISTORY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MULTIMODALITY CANCER THERAPY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; SENSITIVITY ANALYSIS;

BREAST NEOPLASMS; CHECKPOINT KINASE 2; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MUTATION;

EID: 84906937926     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.306     Document Type: Article

References (34)

1. Bayraktar S, Gluck S (2012) Systemic therapy options in BRCA mutationassociated breast cancer. Breast Cancer Res Treat 135: 355-366.
2. Bertelsen L, Bernstein L, Olsen JH, Mellemkjaer L, Haile RW, Lynch CF, Malone KE, Anton-Culver H, Christensen J, Langholz B, Thomas DC, Begg CB, Capanu M, Ejlertsen B, Stovall M, Boice JD, Shore RE, Bernstein JL (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 100: 32-40.
3. Brekelmans CT, Seynaeve C, Menke-Pluymers M, Bruggenwirth HT, Tilanus-Linthorst MM, Bartels CC, Kriege M, van Geel AN, Crepin CM, Blom JC, Meijers-Heijboer H, Klijn JG (2006) Survival and prognostic factors in BRCA1-associated breast cancer. Ann Oncol 17: 391-400.
4. Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, van Leeuwen FE, 't Veer LJ (2007) Identification of women with an increased risk of developing radiationinduced breast cancer: a case only study. Breast Cancer Res 9: R26.
5. Broeks A, de Witte L, Nooijen A, Huseinovic A, Klijn JG, van Leeuwen FE, Russell NS, van't Veer LJ (2004) Excess risk for contralateral breast cancer in CHEK21100delC germline mutation carriers. Breast Cancer Res Treat 83: 91-93.
6. Cybulski C, Wokolorczyk D, Jakubowska A, Huzarski T, Byrski T, Gronwald J, Masojc B, Deebniak T, Gorski B, Blecharz P, Narod SA, Lubinski J (2011) Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 29: 3747-3752.
7. de Bock GH, Mourits MJ, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG (2006) Association between the CHEK21100delC germ line mutation and estrogen receptor status. Int J Gynecol Cancer 16(Suppl 2): 552-555.
8. de Bock GH, Schutte M, Krol-Warmerdam EM, Seynaeve C, Blom J, Brekelmans CT, Meijers-Heijboer H, van Asperen CJ, Cornelisse CJ, Devilee P, Tollenaar RA, Klijn JG (2004) Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK21100delC variant. J Med Genet 41: 731-735.
9. Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK (2009) Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27: 5887-5892.
10. Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, Bale AE, Alvarez-Franco M (2002) Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 359: 1471-1477.
11. Hollestelle A, Wasielewski M, Martens JWM, Schutte M (2010) Discovering moderate-risk breast cancer susceptibility genes. Curr Opin Genet Dev 20: 268-276.
12. Jekimovs CR, Chen X, Arnold J, Gatei M, Richard DJ, Spurdle AB, Khanna KK, Chenevix-Trench G (2005) Low frequency of CHEK2 1100delC allele in Australian multiple-case breast cancer families: functional analysis in heterozygous individuals. Br J Cancer 92: 784-790.
13. Kilpivaara O, Laiho P, Aaltonen LA, Nevanlinna H (2003) CHEK2 1100delC and colorectal cancer. J Med Genet 40: e110.
14. Kleinbaum DG, Klein M (2005) Survival Analysis. Springer: New York, USA.
15. Kriege M, Seynaeve C, Meijers-Heijboer H, Collee JM, Menke-Pluymers MB, Bartels CC, Tilanus-Linthorst MM, Blom J, Huijskens E, Jager A, van den OA, van Geel B, Hooning MJ, Brekelmans CT, Klijn JG (2009) Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 27: 3764-3771.
16. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, De Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T, Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR (2002) Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55-59.
17. Mellemkjaer L, Dahl C, Olsen JH, Bertelsen L, Guldberg P, Christensen J, Borresen-Dale AL, Stovall M, Langholz B, Bernstein L, Lynch CF, Malone KE, Haile RW, Andersson M, Thomas DC, Concannon P, Capanu M, Boice JD, Bernstein JL (2008) Risk for contralateral breast cancer among carriers of the CHEK21100delC mutation in the WECARE Study. Br J Cancer 98: 728-733.
18. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade OI, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD, Narod SA (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22: 2328-2335.
19. Nagel JHA, Peeters JK, Smid M, Sieuwerts AM, Wasielewski M, de Weerd V, Trapman-Jansen AMAC, van den Ouweland A, Bruggenwirth H, van IJcken WFJ, Klijn JGM, van der Spek PJ, Foekens JA, Martens JWM, Schutte M, Meijers-Heijboer H (2012) Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. Br Cancer Res Treat 132: 439-448.
20. Nevanlinna H, Bartek J (2006) The CHEK2 gene and inherited breast cancer susceptibility. Oncogene 25: 5912-5919.
21. Pierce LJ, Levin AM, Rebbeck TR, Ben-David MA, Friedman E, Solin LJ, Harris EE, Gaffney DK, Haffty BG, Dawson LA, Narod SA, Olivotto IA, Eisen A, Whelan TJ, Olopade OI, Isaacs C, Merajver SD, Wong JS, Garber JE, Weber BL (2006) Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 24: 2437-2443.
22. Reding KW, Bernstein JL, Langholz BM, Bernstein L, Haile RW, Begg CB, Lynch CF, Concannon P, Borg A, Teraoka SN, Torngren T, Diep A, Xue S, Bertelsen L, Liang X, Reiner AS, Capanu M, Malone KE, Group WCS (2010) Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer. Breast Cancer Res Treat 123: 491-498.
23. Riaz M, EMJJ Berns, Sieuwerts AM, Ruigrok-Ritstier K, de Weerd V, Groenewoud A, Uitterlinden AG, Look MP, Klijn JGM, Sleijfer S, Foekens JA, Martens JWM (2012) Correlation of breast cancer susceptibility loci with patient characteristics, metastasis-free survival, and mRNA expression of the nearest genes. Breast Cancer Res Treat 133: 843-851.
24. Robson M, Svahn T, McCormick B, Borgen P, Hudis CA, Norton L, Offit K (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. Cancer 103: 44-51.
25. Roeb W, Higgins J, King MC (2012) Response to DNA damage of CHEK2 missense mutations in familial breast cancer. Hum Mol Genet 21: 2738-2744.
26. Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, van't Veer LJ (2007) Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK21100delC germline mutation. J Clin Oncol 25: 64-69.
27. Sodha N, Bullock S, Taylor R, Mitchell G, Guertl-Lackner B, Williams RD, Bevan S, Bishop K, McGuire S, Houlston RS, Eeles RA (2002) CHEK2 variants in susceptibility to breast cancer and evidence of retention of the wild type allele in tumours. Br J Cancer 87: 1445-1448.
28. The CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK21100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9065 controls from 10 studies. Am J Hum Genet 74: 1175-1182.
29. The CHEK2-Breast Cancer Consortium (2002) Low-penetrance susceptibility to breast cancer due to CHEK21100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 31: 55-59.
30. Tung N (2011) Management of women with BRCA mutations: a 41-year-old woman with a BRCA mutation and a recent history of breast cancer. JAMA 305: 2211-2220.
31. Tung N, Silver DP (2011) Chek2 DNA damage response pathway and inherited breast cancer risk. J Clin Oncol 29: 3813-3815.
32. van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJE, de Vries J, van der Hout AH, Oosterwijk JC (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Br Cancer Res Treat 124: 643-651.
33. Weischer M, Bojesen SE, Ellervik C, Tybjaerg-Hansen A, Nordestgaard BG (2008) CHEK21100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls. J Clin Oncol 26: 542-548.
34. Weischer M, Nordestgaard BG, Pharoah P, Bolla MK, Nevanlinna H, Van't Veer LJ, Garcia-Closas M, Hopper JL, Hall P, Andrulis IL, Devilee P, Fasching PA, Anton-Culver H, Lambrechts D, Hooning M, Cox A, Giles GG, Burwinkel B, Lindblom A, Couch FJ, Mannermaa A, Grenaker Alnaes G, John EM, Dork T, Flyger H, Dunning AM, Wang Q, Muranen TA, van Hien R, Figueroa J, Southey MC, Czene K, Knight JA, Tollenaar RA, Beckmann MW, Ziogas A, Christiaens MR, Collee JM, Reed MW, Severi G, Marme F, Margolin S, Olson JE, Kosma VM, Kristensen VN, Miron A, Bogdanova N, Shah M, Blomqvist C, Broeks A, Sherman M, Phillips KA, Li J, Liu J, Glendon G, Seynaeve C, Ekici AB, Leunen K, Kriege M, Cross SS, Baglietto L, Sohn C, Wang X, Kataja V, Borresen-Dale AL, Meyer A, Easton DF, Schmidt MK, Bojesen SE (2012) CHEK21100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 30: 4308-4316.